

Short Communication

Probiotic yogurt in the elderly with intestinal bacterial overgrowth: endotoxaemia and innate immune functions

Eduardo J. Schiffrin^{1*}, Alexandr Parlesak², Christiane Bode², J. Christian Bode², Martin A. van't Hof¹, Dominik Grathwohl¹ and Yves Guigoz¹

¹Nestlé Research Center, 1000 Lausanne 26, Switzerland

²Department of Physiology of Nutrition, Hohenheim University, 70599, Stuttgart, Germany

(Received 8 February 2008 – Revised 6 June 2008 – Accepted 7 June 2008 – First published online 25 September 2008)

A study was conducted in healthy elderly living independently in senior housing to assess the impact of a probiotic yoghurt supplement on small intestinal bacterial overgrowth. Twenty-three participants with positive and thirteen participants with negative hydrogen breath test were studied before and after a period of 4 weeks of probiotic yoghurt administration. Intestinal permeability, plasma endotoxin levels, phagocytic activity of leucocytes, cytokine production by monocytes and free radical response of neutrophils were determined. Intestinal permeability was similar for the two groups and was unaffected by probiotic treatment. Both plasma endotoxin levels and the basal phagocytic activity of leucocytes decreased after yoghurt intake in the two groups. Exposure of monocytes and neutrophils *ex vivo* led to an increased cytokine response and free radical response, respectively. The normalisation of the various cytokine responses was more apparent in the group with positive breath test. In addition, the plasma levels of lipopolysaccharide binding protein and soluble CD14, lipopolysaccharide pattern recognition receptors and surrogate markers of lipopolysaccharide permeability were diminished by the end of the study. In conclusion, probiotic administration in the elderly normalises the response to endotoxin, and modulates activation markers in blood phagocytes, and therefore may help reduce low-grade chronic inflammation.

Probiotics: Immunity: Elderly: Small-intestinal bacterial overgrowth

Small-intestinal bacterial overgrowth (SIBO) should always be suspected in elderly subjects that suffer from chronic diarrhoea, anorexia or nausea⁽¹⁾. It has been defined quantitatively as more than 10⁵ colony-forming units/ml of bacteria in the fluid of the proximal small bowel and can be associated with malabsorption and malnutrition in the elderly⁽²⁾.

The relatively high prevalence of SIBO in the elderly may result from hypochlorhydria caused by atrophic gastritis or by antacid treatments⁽³⁾. However, mucosal dysmotility, frequently associated with type 2 diabetes, and alterations of the mucosal immune system⁽⁴⁾ can also be contributing factors. Besides causing impairment of digestive and absorptive function SIBO is also frequently associated with increased intestinal permeability⁽⁵⁾. The passage of bacterial products into the intestinal mucosa and the portal vein may play an important role in the altered intestinal digestive/absorptive function, the metabolism, and the low-grade inflammation in the elderly. Administration of probiotic-containing yoghurt may improve the clinical condition by improving gut barrier function and by its antibacterial, immunomodulatory and/or anti-inflammatory effects⁽⁶⁾.

The current study examined the effects of an orally administered probiotic-containing yoghurt in an elderly population with a positive glucose/H₂ breath test, and as such a suspected SIBO, compared to those with a negative glucose/H₂ breath test. More specifically, effects on intestinal colonisation, gut permeability, endotoxin translocation and modification of innate immune functions were assessed.

Methods

Population/study design and product administration

Elderly subjects of both sexes (aged 61–94, mean 76.9 (SD 7.3) years) were recruited from a random sample of 294 elderly subjects that participated in a cross-sectional survey study conducted to determine the prevalence of SIBO based on the excretion in exhaled breath of hydrogen generated by the metabolism of glucose by intestinal bacteria^(7,8). Volunteers were not included if they were suffering from viral or bacterial infections, had been under antibiotics in the preceding 3 weeks, or suffered from any acute or chronic disease

Abbreviations: LBP, lipopolysaccharide binding protein; LPS, lipopolysaccharide; ppm, parts per million; sCD14, soluble CD14; SIBO, small-intestinal bacterial overgrowth; SNH, subjects with negative breath tests; SPH, subjects with positive breath test.

* **Corresponding author:** Dr Eduardo J. Schiffrin, Nestlé Nutrition, Nestec Ltd, Avenue Reller 22, CH-1800 Vevey, Switzerland, fax +41 21 924 7894, email Eduardo.Schiffrin@nestle.com

including malignancies, or had been subjected to any form of gastro-intestinal surgery. The prevalence of SIBO found with the H₂ breath test was 15 %⁽⁸⁾.

Twenty-three elderly subjects (eighteen women, five men) with positive breath test (SPH) and thirteen subjects (nine women, four men) with negative breath test (SNH) were included in a follow-up, where the yogurt was administered (observational study with one treatment group).

Subjects repeated the breath test at the beginning of the study and were asked to consume probiotic yogurt (2 × 150 g) *Lactobacillus johnsonii* La1 (daily dose of 10⁹ colony-forming units) for 4 weeks with a previous restriction of 2 weeks for yoghurt, kefir or butter milk. During the 4-week consumption of the study subjects were not allowed to consume other fermented products. No other advice with regard to diet was given to the participants. They were allowed to continue routine treatment and medication for stable conditions.

Hydrogen breath test

Hydrogen concentration (parts per million; ppm) in exhaled air was determined after ingestion of 50 g glucose as described by Parlesak *et al.*⁽⁸⁾. A positive result of the H₂ test was taken as a rise of at least 10 ppm of expired H₂ over baseline within 75 min. The breath test was performed at the baseline (prevalence study⁽⁸⁾), before probiotic administration (1 week later) and after the 4 weeks of probiotic yoghurt consumption.

Intestinal permeability assessment was performed with polyethylene glycol of different molecular weights (400, 1500, 4000, 10 000) as previously described⁽⁹⁾.

Endotoxin determination was carried out before and after probiotic yoghurt consumption in peripheral venous blood as previously described^(10,11).

Ex vivo phagocytic activity and cytokine production after stimulation with lipopolysaccharide (LPS) (*Escherichia coli* 0111:B4) was performed on peripheral blood mononuclear cells.

Phagocytosis in human whole blood was performed using opsonised, fluorescein isothiocyanate-labelled *E. coli* (PHAGOTEST™; Becton Dickinson, Basel, Switzerland) and flow cytometry as described previously⁽¹²⁾.

For the determination of cytokine release by monocytes peripheral blood mononuclear cells were separated from whole blood by gradient centrifugation with Ficoll[®].

Cytokine production by monocytes was determined as follows: monocytes were purified by adhesion to plastic dishes during 1.5 h. Cells were thereafter stimulated by the addition of 10 ng/ml endotoxin from *E. coli* 0111:B4 (Sigma, Stuttgart, Germany). Cell culture supernatants were collected at 2.5 h for the determination of TNF-α and IL-1β and at 20 h for the determination of IL-10. Cytokine concentrations were measured with commercially available ELISA kits (Pharmingen, Heidelberg, Germany).

Release of reactive oxygen species by neutrophils procedure and evaluation are described in detail in a previous publication⁽¹³⁾. Neutrophils were isolated from whole blood by gradient centrifugation with Polymorphprep (Nycomed, Oslo, Norway). The chemiluminescence emitted by the LPS-stimulated neutrophils from SPH and SNH groups was assessed as the area under the curve in an assay that covers 1 h post-stimulation with different LPS concentrations.

Statistical analysis

The study presented has to be considered as an exploratory clinical trial. The design consists of one treatment group. The effect of the yogurt was investigated by a pre-post comparison. The observed differences may be due to treatment, but also due to 'regression to the mean' as well as due to unknown confounders. Measurements of H₂ breath test are not approximately normally distributed. Also log transformation did not achieve the desired distributional characteristics. Consequently summary statistics are presented by median and quartiles and inferential statistics is performed by Wilcoxon sign-rank test. Treatment differences and CI are estimated according to Hodges & Lehmann⁽¹⁴⁾.

The other outcomes are approximately normally or log-normally distributed. Summary statistics are presented by means and their standard errors. Inferential statistics was performed by the *t* test. We are aware that our exploratory research may produce also false positive results. Therefore the *P* values presented throughout this report are interpreted as flags in order to indicate an interesting result. This interpretation is also in agreement with the international conference of harmonisation guideline, ICH E9.

Results

From the 294 subjects, only 279 subjects were further investigated in the cross-sectional screening study (data not shown). In this sample, thirty-eight elderly showed a positive hydrogen breath test (SPH) and 241 showed a negative hydrogen breath test (SNH). The cut point was 10 ppm. SPH elderly, showing compliance, were invited to participate in next stage of the study, resulting in twenty-three SPH participants (eighteen women, five men). Additionally thirteen SNH elderly were enrolled in the study (nine women, four men). The mean age was 78.6 (SD 7.8) and 77.5 (SD 5.8) years for the SPH and SNH subjects, respectively. Both groups were comparable in anthropometric data (weight 66 (SD 15) and 71 (SD 12) kg; BMI 24.0 (SD 3.8) and 25.8 (SD 3.6) kg/m² for SPH and SNH elderly, respectively).

The H₂ breath test was performed three times in each subject, on screening, before and on the last day of yogurt consumption, 4 weeks later.

Development over time of the H₂ hydrogen breath test for each observation group (SPH, SNH) is presented in Fig. 1. The SPH subjects are showing a significant decrease (−18 ppm; 95 % CI −34.5, −7.5; *P*=0.006) from screening until start of yogurt intake and then are remaining relatively stable until end of yogurt intake (+1.0 ppm; 95 % CI −13.5, 12.0; *P*=0.87). SNH subjects were consistently negative (<10 ppm) in all three determinations and do not show relevant changes from screening until start (−0.5 ppm; 95 % CI −3.0, 2.5; *P*=0.75) and until end of yogurt intake (±0.0 ppm; 95 % CI −2.5, 2.0; *P*=0.80).

Intestinal permeability

No significant association of increased intestinal permeability to macromolecules (polyethylene glycol) with small bowel intestinal overgrowth was observed, and no change was observed as a result of the probiotic yogurt intake (data not shown).




Fig. 1. Boxplots of hydrogen breath test grouped by negative (–) and positive (+) tests at baseline. Base, baseline; Pre, before probiotic intake (1 week after baseline); Post, after 4-week probiotic intake. ●, Median value; ○, outliers; box, interquartile range; whiskers, last outlier not further away than 1.6 times interquartile range (corresponding to 95% CI for the median); ppm, parts per million; . . . , the 10 ppm threshold for a normal breath test.

Endotoxin concentration

Before treatment no differences were observed for endotoxin concentrations in peripheral venous blood between subjects of the different groups (6.49 (SEM 8.1) for SPH *v.* 6.4 (SEM 6.3) pg/ml for the SNH group; Fig. 2). After the 4 weeks of probiotic yogurt consumption a trend towards a diminution of endotoxin concentration was observed in the SPH group (6.49 (SEM 8.1) *v.* 4.6 (SEM 5.6) pg/ml). While in the SNH group plasma endotoxin was significantly lower after probiotic yoghurt consumption (6.4 (SEM 6.3) *v.* 0.5 (SEM 0.0) pg/ml, $P=0.043$, before *v.* after).




Fig. 2. Endotoxin concentrations in plasma of subjects with positive breath test (SPH, □) and subjects with negative breath tests (SNH, ▨) before and at the end of the yoghurt consumption period. Values are means with their standard errors depicted by vertical bars. Mean value was significantly different from that before the yoghurt consumption period: * $P=0.043$.

Haematological parameters

Complete blood cell count, erythrocyte sedimentation, total plasma protein, albumin, C-reactive protein and parameters associated to liver, renal and immune functions were analysed before and after the probiotic yogurt consumption. The groups were not different at the start of the ingestion period and no clinically significant changes were observed at the end (data not shown).

Soluble CD14 (sCD14) plays a pivotal role in LPS recognition of LPS-induced cell activation. LPS binding protein (LBP) is a class 1 acute-phase protein with the ability to bind and transfer bacterial LPS to CD14 receptor⁽¹⁵⁾. sCD14 and LBP were studied only in the SPH group, due to the more restricted size of the SNH group. Plasma levels of soluble sCD14 and LBP showed a significant decrease after the yogurt intake period (3.806 (SEM 0.706) *v.* 3.580 (SEM 0.615) $\mu\text{g/ml}$ for sCD14, $P=0.04$) and (31 (SEM 23) *v.* 24 (SEM 20) $\mu\text{g/ml}$ for LBP, $P=0.03$).

Phagocytic activity of monocytes and neutrophils

No differences in the percentage of phagocytes were observed between groups at the beginning of the study and there was no significant change after the 4 weeks of intervention. The mean fluorescence intensity is proportional to the number of incorporated bacteria by individual phagocytes. Mean fluorescence intensity decreased after the consumption of probiotic yogurt in both groups for monocytes and neutrophils (monocytes, $P=0.011$ and neutrophils, $P=0.0001$ in SPH group; monocytes, $P=0.036$ and neutrophils, $P=0.036$ in SNH group).

Cytokine release

Before yogurt consumption, monocytes isolated from subjects of the SPH group produced significantly less IL-1 β and IL-10 than subjects in the SNH group (199 (SEM 359) *v.* 586 (SEM 566) pg/ml, $P=0.035$ for IL-1 β and 759 (SEM 739) *v.* 1846 (SEM 1309) pg/ml, $P=0.009$ for IL-10). After 4 weeks of yoghurt consumption monocytes from SPH participants showed an increased capacity to react to endotoxin challenge attaining similar levels to the SNH group.

Release of reactive oxygen species

A trend towards a more elevated release of reactive oxygen species by neutrophils was observed after the yogurt consumption in both groups. The differences were statistically significant at the highest LPS concentration in the SPH group ($P=0.031$; see Fig. 3). Reactive oxygen species production by neutrophils from the SNH group (data not shown) showed a similar pattern, higher after probiotic yoghurt consumption, but in this case did not reach statistical significance.

Discussion

All participants had a good nutritional status and no apparent clinical manifestation of SIBO. Of the SPH subjects enrolled in the present study 43% did not reach the threshold increment of 10 ppm of H₂ in the second breath test before the start of probiotic yoghurt consumption. On the other hand, none of




Fig. 3. Release of reactive oxygen species (ROS) by neutrophils isolated from subjects with positive breath test before (□) and at the end (■) of the yoghurt consumption period. ($P=0.0311$ for endotoxin highest dose, NS for the rest of concentrations). Values are means with their standard errors depicted by vertical bars.

the thirteen SNH subjects had a positive H_2 breath test in the second or third breath tests. The spontaneous normalisation of a positive H_2 breath test in the SPH group may be due to various factors.

According to most authors, the sensitivity of glucose/ H_2 breath test is approximately 70% and the specificity is about 80%. Thus the apparent discrepancy between the first and the second breath tests performed 1 week apart cannot be attributed to inherent limitations of the test alone⁽¹⁶⁾.

The lack of reproducibility in the test may be due to physiological or pathophysiological variations such as carbohydrate malabsorption, gastrointestinal motor disorders with transit abnormalities⁽¹⁷⁾. The stability of the intestinal bacterial population varies in both the number and type of colonising bacteria. The washout effect of diarrhoeal episodes, the loss of bacterial flora due to antibiotic use, and acidity of the bowel lumen may all contribute to such fluctuations⁽⁶⁾. Although the study participants were not treated with antibiotics, we cannot discount transient diarrhoeal episodes, changes in bowel motility and evacuation, or other factors which may have contributed to the spontaneous reduction in bacterial overgrowth observed in ten of the twenty-three SPH subjects. Interestingly, seven of these SPH participants are once again positive in the third test after the intervention. None of the SNH subjects had a positive response in either the second or third test. This highly significant difference (7/10 v. 0/13, $P=0.0003$) supports the grouping of the participants on the basis of SIBO. At the end of yoghurt consumption no changes in the glucose/ H_2 breath test were observed for either of the groups.

SIBO can increase intestinal permeability assessed by the lactulose/mannitol test⁽⁵⁾. Subjects with overgrowth of colonic-like bacteria appear to have more compromised barrier integrity and higher inflammatory response than subjects colonised by other types of microbiota⁽⁵⁾. In the present study, the SPH and SNH subjects did not differ in their intestinal

permeability to polyethylene glycol of different molecular weights. The consumption of probiotic yoghurt for 4 weeks did not influence this permeability.

SIBO can be associated with an increased immune-inflammatory activity of the mucosal immune-competent cells. Increased production of IL-6, higher numbers of intra-epithelial lymphocytes and of IgA-producing cells have been associated with the intestinal bacterial load⁽¹⁸⁾. The inflammatory/immune reaction seems to be mediated by a coliform predominant microbiota.

In addition to the local effect of SIBO in the mucosal immune compartment, leakage or translocation of bacteria or their components into the body can contribute to visceral toxicity, systemic inflammatory conditions and metabolic changes. SIBO and passage of LPS into the portal vein can be deleterious to the liver and contribute to non-alcoholic liver disease^(19,20).

It has been postulated that the subclinical inflammatory status observed in a subgroup of elderly may be propagated from components in the intestinal environment as a consequence of a poor mucosal barrier and inadequate mucosal clearance of the abnormally high bacterial challenge⁽²¹⁾.

There is no strong evidence supporting an association between translocation bacteria or their products and increased intestinal permeability⁽²²⁾. Therefore, the unaltered permeability to polyethylene glycol does not rule out a closer interaction of the mucosal immune cells with the abnormally high bacterial load of the small bowel and a concomitant increase in lamina propria cellularity⁽²³⁾, due to macrophage and lymphocyte infiltration. Increased local IL-6 production is related to the activation of lamina propria mononuclear cells exposed to higher LPS levels. Local mucosal changes may not be detected systemically.

Positive glucose/ H_2 breath test was not associated with higher levels of plasma LPS as both groups had similar concentrations at baseline. After the consumption of the probiotic yoghurt a significant decrease in plasma endotoxin was observed in the SNH group and a similar trend was present in the SPH group (Fig. 2). Since probiotic ingestion did not alter breath test results or permeability to polyethylene glycol, one can assume that the observed cellular changes are due to other mechanisms besides a change in the bacterial load of the small bowel or a compromise of mucosal barrier integrity. An altered small bowel microbiota with lower quantities of coliform endotoxin-producing bacteria may have resulted from probiotic administration. Alternatively probiotic administration may activate the innate macrophage system⁽¹²⁾ in the mucosal compartment and thereby improve LPS clearance. Certainly, removal and clearance of LPS from the body is another of the many functions associated with the intestinal cellular compartment⁽²⁴⁾. In experimental conditions lamina propria macrophages and intestinal epithelial cells take up and clear LPS⁽²⁴⁾. These cells are probably also involved in the clearance of lumenally derived endotoxin and translocating bacteria. Long-term exposure to endotoxin may render phagocytes tolerant to LPS and incapable of mounting an energetic response to further challenge with bacterial products and endotoxin in particular. It is feasible that innate immune cells have a permanently low level of activation but paradoxically, lose their capacity to mount an effective response when needed. This can be clearly observed in the extreme case of

liver cirrhosis⁽²⁵⁾. In the present study the decreased *ex vivo* phagocytic capacity of unstimulated individual cells after probiotic intake suggests a decrease in basal low-grade cellular activation in the elderly. In contrast, monocytes stimulated *ex vivo* with endotoxin had a low response of cytokine production that was increased after the consumption of probiotic yoghurt. This change was significant in the SPH group.

The release of reactive oxygen species by neutrophils exposed to endotoxin was similar before and after probiotic intake, but a higher reactivity to increasing concentrations of endotoxin was observed after probiotic administration.

Although we have no direct proof of endotoxin leakage at the gut level there is some evidence to suggest that LBP, sCD14 and possibly other LPS pattern recognition receptors are important parameters for monitoring the host acute-phase reaction secondary to bacterial product leakage into the internal milieu. After the probiotic yoghurt administration a significant decrease in sCD14 and LBP plasma levels was observed.

In conclusion, monocytes and neutrophils exhibited a higher phagocytic capacity before probiotic consumption if no challenge with LPS was performed *ex vivo*. In contrast, probiotic administration normalised responsiveness to LPS *ex vivo* and resulted in an increased production of cytokines and free radicals.

A unifying explanation is that probiotic administration probably results in a lower exposure to endotoxin in the mucosal microenvironment and in the body. This lower exposure may be due to a qualitative switch from a Gram-negative endotoxin-producing microbiota to a Gram-positive (less pro-inflammatory) type of microbiota in the proximal small bowel⁽²¹⁾, and/or an activation of the innate immune system by probiotics that results in better clearance of endotoxin and improved immunocompetence.

Probiotics have been extensively studied for their health-promoting activities in a variety of human conditions where altered bacterial ecology seems to play a pathogenetic role. The distal small bowel and the colon are where most intestinal bacteria find their ecological niches and where probiotics may also find a more favourable environment. Here we explored the possibility that probiotics exert effects on abnormal bacterial communities along the entire length of the small bowel. The probiotic effect we observed may be mediated by different mechanisms: (1) competitive exclusion of colonising bacteria that are vying for the same ecological niches with subsequent qualitative changes in the composition of the microbiota; (2) stimulation of immune function and improvement of immune competence for controlling the levels of the bacterial populations; (3) increase in innate immune function and endotoxin clearance; and/or (4) the induction by probiotics of a homeostatic mucosal immune response that can compensate for the pro-inflammatory activity of the colonic-like bacteria. Any one of the aforementioned effects alone or in combination could be of benefit in subjects with SIBO.

The present clinical study suggests that the administration of supplements in the elderly may benefit from the addition of ingredients that improve the composition of the intestinal microbiota. Moreover, the present results indicate that an altered intestinal ecology underlies the low-grade inflammatory status that favours catabolism and loss of lean body mass in the elderly.

Acknowledgements

We are indebted to Mrs A. Bleher and S. Berhard for support in recording the diet histories and instructing the study participants during the breath tests. The work was generously supported by Nestec Ltd. The authors made the following contributions to the study: E. J. S. and A. P.: study concept and design, analysis and interpretation of data, preparation of the manuscript; C. B. and J. C. B.: study concept and design, subject recruitment, acquisition of data; M. A. v. H. and D. G.: analysis and interpretation of data; Y. G.: interpretation of data, preparation of the manuscript. A. P., C. B. and J. C. B. have no conflict of interest. E. J. S., M. A. v. H., D. G. and Y. G. are employees of Nestec Ltd, an affiliate of Nestlé SA, Switzerland.

References

1. Donald IP, Kitchingmam G, Donald F & Kupfer RM (1992) The diagnosis of small bowel bacterial overgrowth in elderly patients. *J Am Geriatr Soc* **40**, 692–696.
2. Riordan SM, McIver CJ, Wakefield D, Bolin TD, Duncombe VM & Thomas MC (1997) Small intestinal bacterial overgrowth in the symptomatic elderly. *Am J Gastroenterol* **92**, 47–51.
3. Saltzman JR, Kowdley KV, Pedrosa MC, Sepe T, Golner B, Perrone G & Russell RM (1994) Bacterial overgrowth without clinical malabsorption in elderly hypochlorhydric subjects. *Gastroenterology* **106**, 615–623.
4. Elphick DA, Chew TS, Higham SE, Bird N, Ahmad A & Sanders DS (2005) Small bowel bacterial overgrowth in symptomatic older people: can it be diagnosed earlier? *Gerontology* **51**, 396–401.
5. Riordan SM, McIver CJ, Thomas DH, Duncombe VM, Bolin TD & Thomas MC (1997) Luminal bacteria and small-intestinal permeability. *Scand J Gastroenterol* **32**, 556–563.
6. Quigley EMM & Quera R (2006) Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. *Gastroenterology* **130**, S78–S90.
7. Romagnuolo J, Schiller D & Bailey RJ (2002) Using breath tests wisely in a gastroenterology practice: an evidence-based review of indications and pitfalls in interpretation. *Am J Gastroenterol* **97**, 1113–1126.
8. Parlesak A, Klein B, Schecher K, Bode JC & Bode C (2003) Prevalence of small bowel bacterial overgrowth and its association with nutrition intake in nonhospitalized older adults. *J Am Geriatr Soc* **51**, 768–773.
9. Parlesak A, Bode JC & Bode C (1994) Parallel determination of gut permeability in man with M(r) 400, M(r) 1500, M(r) 4000 and M(r) 10,000 polyethylene glycol. *Eur J Clin Chem Clin Biochem* **32**, 813–820.
10. Fukui H, Brauner B, Bode JC & Bode C (1991) Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay 463. *J Hepatol* **12**, 162–169.
11. Fukui H, Brauner B, Bode JC & Bode C (1989) Chromogenic endotoxin assay in plasma. Selection of plasma pretreatment and production of standard curves. *J Clin Chem Clin Biochem* **27**, 941–946.
12. Donnet-Hughes A, Rochat F, Serrant P, Aeschlimann JM & Schiffrin EJ (1999) Modulation of nonspecific mechanisms of defense by lactic acid bacteria: effective dose. *J Dairy Sci* **82**, 863–869.
13. Parlesak A, Diedrich JP, Schafer C & Bode C (1998) A low concentration of ethanol reduces the chemiluminescence of human granulocytes and monocytes but not the tumor necrosis

- factor alpha production by monocytes after endotoxin stimulation. *Infect Immun* **66**, 2809–2813.
14. Hodges JL & Lehmann EL (1963) Estimates of location based on rank tests. *Ann Math Stat* **34**, 598–611.
 15. Schumann RR & Zweigner J (1999) A novel acute-phase marker: lipopolysaccharide binding protein (LBP). *Clin Chem Lab Med* **37**, 271–274.
 16. Kerlin P & Wong L (1988) Breath hydrogen testing in bacterial overgrowth of the small intestine. *Gastroenterology* **95**, 982–988.
 17. Simren M & Stotzer PO (2006) Use and abuse of hydrogen breath tests. *Gut* **55**, 297–303.
 18. Kett K, Baklien K, Bakken A, Kral JG, Fausa O & Brandtzaeg P (1995) Intestinal B-cell isotype response in relation to local bacterial load: evidence for immunoglobulin A subclass adaptation. *Gastroenterology* **109**, 819–825.
 19. Angulo P (2002) Nonalcoholic fatty liver disease. *N Engl J Med* **346**, 1221–1231.
 20. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH & Cummins AG (2001) The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. *Gut* **48**, 206–211.
 21. Guigoz Y, Dore J & Schiffrin EJ (2008) The inflammatory status of old age can be nurtured from the intestinal environment. *Curr Opin Clin Nutr Metab Care* **11**, 13–20.
 22. O'Boyle CJ, MacFie J, Dave K, Sagar PS, Poon P & Mitchell CJ (1998) Alterations in intestinal barrier function do not predispose to translocation of enteric bacteria in gastroenterologic patients. *Nutrition* **14**, 358–362.
 23. Welsh FKS, Farmery SM, MacLennan K, Sheridan MB, Barclay GR, Guillou PJ & Reynolds JV (1998) Gut barrier function in malnourished patients. *Gut* **42**, 396–401.
 24. Ge Y, Ezzell R & Warren HS (2000) Localization of endotoxin in the rat intestinal epithelium. *J Infect Dis* **182**, 873–881.
 25. Lin CY, Tsai IF, Ho YP, Huang CT, Lin YC, Lin CJ, Tseng SC, Lin WP, Chen WT & Sheen IS (2007) Endotoxemia contributes to the immune paralysis in patients with cirrhosis. *J Hepatol* **46**, 816–826.